Vaxcyte (PCVX) CEO sells 18,198 shares after option exercise

Rhea-AI Filing Summary

Vaxcyte, Inc. chief executive Grant Pickering exercised stock options for 16,198 shares of common stock at an exercise price of $2.03 per share on July 27, 2026. He then sold 18,198 common shares in market transactions at prices between $54.77 and $56.18 per share under a Rule 10b5-1 trading plan, including sales by trusts for his children. After the derivative transaction, 137,000 option shares remain exercisable.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 8 txns

Insider PICKERING GRANT

Role CHIEF EXECUTIVE OFFICER

Sold 18,198 shs ($1.01M)

Approx. gross sale proceeds $1.01M

Approx. exercise cost $33K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) F10	16,198	$0.00	$0.00
Exercise	Common Stock F1	16,198	$2.03	$33K
Sale	Common Stock F2, F3	11,783	$55.515	$654K
Sale	Common Stock F2, F4	4,415	$55.931	$247K
Sale	Common Stock F2, F5, F6	756	$55.516	$42K
Sale	Common Stock F2, F7, F6	244	$55.964	$14K
Sale	Common Stock F2, F5, F8	622	$55.54	$35K
Sale	Common Stock F2, F9, F8	378	$55.914	$21K

Holdings After Transaction: Stock Option (right to buy) — 137,000 shares (Direct); Common Stock — 453,247 shares (Direct); Common Stock — 133,215 shares (Indirect, By Children's Trust)

Footnotes (10)

1. F1. Includes 781 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2026.
2. F2. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026.
3. F3. The price reported is a weighted-average price. The shares were sold at prices ranging from $54.77 to $55.765. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
4. F4. The price reported is a weighted-average price. The shares were sold at prices ranging from $55.77 to $56.13. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
5. F5. The price reported is a weighted-average price. The shares were sold at prices ranging from $54.77 to $55.71. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
6. F6. Shares are held directly by a trust for the benefit of the Reporting Person's son.
7. F7. The price reported is a weighted-average price. The shares were sold at prices ranging from $55.81 to $56.18. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
8. F8. Shares are held directly by a trust for the benefit of the Reporting Person's daughter.
9. F9. The price reported is a weighted-average price. The shares were sold at prices ranging from $55.82 to $56.085. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
10. F10. Option is fully vested and exercisable.

Key Figures

Options exercised: 16,198 shares Exercise price: $2.03 per share Common shares sold (total): 18,198 shares +4 more

7 metrics

Options exercised 16,198 shares Stock options for common stock exercised on July 27, 2026 at $2.03 per share

Exercise price $2.03 per share Exercise price of options converted into 16,198 Vaxcyte common shares

Common shares sold (total) 18,198 shares Aggregate number of Vaxcyte common shares sold in all July 27, 2026 transactions

Direct sale tranche 1 11,783 shares at $55.515 Direct common stock sale at a weighted-average price with trades from $54.77 to $55.765

Direct sale tranche 2 4,415 shares at $55.931 Direct common stock sale at a weighted-average price with trades from $55.77 to $56.13

Indirect sale (son’s trust) 756 shares Shares held by a trust for the benefit of the reporting person’s son sold at prices from $54.77 to $55.71

Options remaining 137,000 shares Stock option shares reported as beneficially owned following the derivative transaction

Key Terms

Rule 10b5-1 trading plan, weighted-average price, Employee Stock Purchase Plan, Stock Option (right to buy)

4 terms

Rule 10b5-1 trading plan regulatory

"The sale reported was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted-average price financial

"The price reported is a weighted-average price, with shares sold across a price range."

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

Employee Stock Purchase Plan financial

"Includes 781 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2026."

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Stock Option (right to buy) financial

"Security title listed as Stock Option (right to buy) with an exercise price of $2.03."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/28/2026 - 04:11 PM Accepted by SEC EDGAR 07/28/2026 - 04:10 PM Learn about SEC filing dates

FAQ

What transactions did Vaxcyte (PCVX) CEO Grant Pickering report on July 27, 2026?

Grant Pickering exercised 16,198 Vaxcyte stock options at $2.03 per share, receiving the same number of common shares. He also sold 18,198 common shares in market trades at prices between $54.77 and $56.18 per share on that date.

How many Vaxcyte (PCVX) shares did Grant Pickering sell and at what prices?

He sold a total of 18,198 Vaxcyte common shares on July 27, 2026. The reported weighted-average sale prices ranged from $54.77 to $56.18 per share, based on several separate market transactions disclosed in the report.

Were Grant Pickering’s Vaxcyte (PCVX) share sales made under a Rule 10b5-1 plan?

Yes. Footnotes state the sales were effected pursuant to a Rule 10b5-1 trading plan adopted on March 3, 2026. The report also affirms the use of a Rule 10b5-1 plan, indicating the sale timing followed a pre-established trading arrangement.

How many Vaxcyte (PCVX) stock options does Grant Pickering still hold after these transactions?

After exercising 16,198 options, Grant Pickering is reported as holding 137,000 option shares. This figure reflects the remaining stock option position reported following the derivative transaction on July 27, 2026, and relates specifically to the option series described.

Did related trusts trade Vaxcyte (PCVX) shares connected to Grant Pickering?

Yes. Trusts for the benefit of Grant Pickering’s son and daughter sold Vaxcyte common shares in several transactions. Individual trades included 756 and 622 shares for one child and 244 and 378 shares for the other, at prices around the disclosed ranges.

Does the Vaxcyte (PCVX) report mention Employee Stock Purchase Plan shares?

Yes. A footnote explains that reported common stock holdings include 781 shares acquired under Vaxcyte’s Employee Stock Purchase Plan on May 15, 2026. This clarifies that a portion of the insider’s beneficial ownership comes from employee stock purchase activity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PICKERING GRANT

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, STE. 300

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/27/2026		M		16,198	A	$2.03	469,445(1)	D
Common Stock	07/27/2026		S(2)		11,783	D	$55.515(3)	457,662	D
Common Stock	07/27/2026		S(2)		4,415	D	$55.931(4)	453,247	D
Common Stock	07/27/2026		S(2)		756	D	$55.516(5)	133,459	I	By Children's Trust(6)
Common Stock	07/27/2026		S(2)		244	D	$55.964(7)	133,215	I	By Children's Trust(6)
Common Stock	07/27/2026		S(2)		622	D	$55.54(5)	133,593	I	By Children's Trust(8)
Common Stock	07/27/2026		S(2)		378	D	$55.914(9)	133,215	I	By Children's Trust(8)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.03	07/27/2026		M			16,198	(10)	07/24/2028	Common Stock	16,198	$0	137,000	D

Explanation of Responses:

1. Includes 781 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2026.

2. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026.

3. The price reported is a weighted-average price. The shares were sold at prices ranging from $54.77 to $55.765. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

4. The price reported is a weighted-average price. The shares were sold at prices ranging from $55.77 to $56.13. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

5. The price reported is a weighted-average price. The shares were sold at prices ranging from $54.77 to $55.71. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

6. Shares are held directly by a trust for the benefit of the Reporting Person's son.

7. The price reported is a weighted-average price. The shares were sold at prices ranging from $55.81 to $56.18. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

8. Shares are held directly by a trust for the benefit of the Reporting Person's daughter.

9. The price reported is a weighted-average price. The shares were sold at prices ranging from $55.82 to $56.085. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

10. Option is fully vested and exercisable.

Remarks:

	Grant Pickering, by /s/ Peter N. Efremenko, Attorney-In-Fact	07/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)